GlassScriptPhysician profile
Alla Yugay
NPI 1649624834
$2,409.94
in general payments reported to CMS, 2019-2025
16 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.66 · 2022: $317 · 2023: $404 · 2024: $484 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024 · Education: $49.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.75 |
| Education | $49.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $766.13 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $328.49 | 2023-2025 | Dupixent |
| Genzyme Corporation | $266.19 | 2023-2025 | |
| United Therapeutics Corporation | $220.31 | 2022-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $179.60 | 2025 | Breztri, Fasenra, Airsupra |
| Insmed, INC. | $164.79 | 2023-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $137.84 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $75.19 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $58.82 | 2025 | Opsynvi, Uptravi |
| Baxter Healthcare | $49.45 | 2025 | Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.81 | 2021-2023 | Ofev |
| Inari Medical, INC. | $35.92 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $30.93 | 2022-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $19.03 | 2023 | Yupelri |
| Philips North America LLC | $17.82 | 2025 | Vest Therapy Und |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.62 | 2023 | Zerbaxa, Recarbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Yugay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.